Press Releases

Press Releases

Date Title  
Oct 28, 2020
Prothena to Report Third Quarter 2020 Financial Results on November 4
DUBLIN, Ireland , Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that
Oct 20, 2020
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
First anti-alpha-synuclein antibody to advance into   confirmatory large study in patients with early P arkinson’s disease ; expected to initiate in 2021 Prothena to earn a $60 million   clinical milestone   upon first patient dosed DUBLIN, Ireland , Oct.
Oct 02, 2020
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
Sep 15, 2020
Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
DUBLIN, Ireland , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investor
Sep 11, 2020
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor function and biomarkers, in patients with early Parkinson’s disease Significantly reduced decline
Sep 08, 2020
Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
DUBLIN, Ireland , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that
Sep 03, 2020
Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
DUBLIN, Ireland , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated
Sep 02, 2020
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
Aug 06, 2020
Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline DUBLIN, Ireland , Aug.
Aug 05, 2020
Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for